Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junzhi Wang

Showing results (1-10 of 246) with videos related to

Pageof 25
Sort By:
Signal Transduction and Targeted Therapy|July 18, 2021
A bivalent recombinant vaccine: a promising strategy against both SARS-CoV-2 variants and wild type of the virusJunzhi Wang
Cellular & Molecular Immunology|November 27, 2020
New strategy for COVID-19 vaccination: targeting the receptor-binding domain of the SARS-CoV-2 spike proteinJunzhi Wang
Clinical & Translational Immunology|December 16, 2014
EV71 vaccine, an invaluable gift for childrenZhenglun Liang, Junzhi Wang
Biologicals : Journal of the International Association of Biological Standardization|September 20, 2011
China's perspective on similar biotherapeutic productsChenggang Liang, Junzhi Wang
Frontiers of Medicine|May 1, 2012
The biopharmaceutical industry in China: history and future perspectivesKai Gao, Junzhi Wang
Molecular Medicine Reports|June 18, 2015
Engineering and characterization of a symbiotic selection-marker-free vector-host system for therapeutic plasmid productionXinchang Shi, Junzhi Wang
Biologicals : Journal of the International Association of Biological Standardization|February 25, 2024
The current status of the biosimilars landscape in ChinaGangling Xu, Junzhi Wang
Frontiers of Medicine|April 16, 2014
The regulatory sciences for stem cell-based medicinal productsBao-Zhu Yuan, Junzhi Wang
Acta Pharmaceutica Sinica. B|February 22, 2020
Optimized functional and structural design of dual-target LMRAP, a bifunctional fusion protein with a 25-amino-acid antitumor peptide and GnRH Fc fragmentMeng Li, Hanmei Xu, Junzhi Wang
Engineering (Beijing, China)|January 31, 2022
Review on Drug Regulatory Science Promoting COVID-19 Vaccine Development in ChinaZhiming Huang, Zhihao Fu, Junzhi Wang
Pageof 25

Showing results (1-10 of 246) with videos related to

Sort By:
Pageof 25
Signal Transduction and Targeted Therapy|July 18, 2021
A bivalent recombinant vaccine: a promising strategy against both SARS-CoV-2 variants and wild type of the virusJunzhi Wang
Cellular & Molecular Immunology|November 27, 2020
New strategy for COVID-19 vaccination: targeting the receptor-binding domain of the SARS-CoV-2 spike proteinJunzhi Wang
Clinical & Translational Immunology|December 16, 2014
EV71 vaccine, an invaluable gift for childrenZhenglun Liang, Junzhi Wang
Biologicals : Journal of the International Association of Biological Standardization|September 20, 2011
China's perspective on similar biotherapeutic productsChenggang Liang, Junzhi Wang
Frontiers of Medicine|May 1, 2012
The biopharmaceutical industry in China: history and future perspectivesKai Gao, Junzhi Wang
Molecular Medicine Reports|June 18, 2015
Engineering and characterization of a symbiotic selection-marker-free vector-host system for therapeutic plasmid productionXinchang Shi, Junzhi Wang
Biologicals : Journal of the International Association of Biological Standardization|February 25, 2024
The current status of the biosimilars landscape in ChinaGangling Xu, Junzhi Wang
Frontiers of Medicine|April 16, 2014
The regulatory sciences for stem cell-based medicinal productsBao-Zhu Yuan, Junzhi Wang
Acta Pharmaceutica Sinica. B|February 22, 2020
Optimized functional and structural design of dual-target LMRAP, a bifunctional fusion protein with a 25-amino-acid antitumor peptide and GnRH Fc fragmentMeng Li, Hanmei Xu, Junzhi Wang
Engineering (Beijing, China)|January 31, 2022
Review on Drug Regulatory Science Promoting COVID-19 Vaccine Development in ChinaZhiming Huang, Zhihao Fu, Junzhi Wang
Pageof 25